Trials / Terminated
TerminatedNCT05784129
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab will be administered subcutaneously. |
| DRUG | Placebo | Placebo will be administered subcutaneously. |
Timeline
- Start date
- 2023-02-21
- Primary completion
- 2023-09-29
- Completion
- 2023-10-10
- First posted
- 2023-03-24
- Last updated
- 2025-04-29
- Results posted
- 2024-10-28
Locations
11 sites across 2 countries: United States, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05784129. Inclusion in this directory is not an endorsement.